Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.60 |
| ▸ | TYK2 | P29597 | 16/20 | 0.60 |
| ▸ | JAK1 | P23458 | 13/20 | 0.60 |
| ▸ | STAT3 | P40763 | 11/20 | 0.60 |
| ▸ | JAK3 | P52333 | 11/20 | 0.60 |
| ▸ | ABL1 | P00519 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.56 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28706992 | 0.82 | JAK2 (0.62) | JAK2TYK2JAK1STAT3JAK3 | |
| SCHEMBL29425714 | 0.82 | JAK2 (0.62) | JAK2TYK2JAK1STAT3JAK3 | |
| SCHEMBL29232088 | 0.79 | JAK2 (0.58) | JAK2TYK2JAK1STAT3JAK3 | |
| SCHEMBL19539430 | 0.71 | JAK2 (0.50) | JAK2TYK2JAK1STAT3JAK3 | |
| SCHEMBL30258437 | 0.69 | JAK2 (0.58) | JAK2TYK2JAK1STAT3JAK3 | |
| SCHEMBL29232075 | 0.69 | JAK2 (0.58) | JAK2TYK2JAK1STAT3JAK3 | |
| SCHEMBL21596384 | 0.69 | KDM5A (0.38) | JAK2TYK2JAK1STAT3JAK3 | |
| SCHEMBL31732415 | 0.69 | KDM5A (0.39) | KDM5A | |
| SCHEMBL30291185 | 0.68 | CDK1 (0.53) | JAK2TYK2JAK1JAK3 | |
| SCHEMBL21596308 | 0.68 | PIK3CD (0.47) | KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236611-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | ALCON INC. (CH) | 2025-07-24 | — | — | US | disclosed |
| EP-4412994-A1 | JANUS KINASE INHIBITING PYRAZOLE COMPOUNDS AND USES THEREOF | Aerie Pharmaceuticals, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118159528-A | Pyrazole compounds that inhibit Janus kinase and uses thereof | 爱瑞制药公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023060202-A1 | JANUS KINASE INHIBITING PYRAZOLE COMPOUNDS AND USES THEREOF | AERIE PHARMACEUTICALS, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236611-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | JAK1, JAK3, JAK2 | JAK2 3/4885TYK2 176/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.